Crescendo Biologics Limited, a Cambridge, UK-based company focused on the discovery and development of human VH antibody fragment therapeutics, a raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing.
Originally announced in December 2013 (read here), the round now totals £19.5m. It was led by Imperial Innovations with participation from new investor Astellas Venture Management (AVM) and seed investor Sofinnova Partners.
The company intends to use the funds to advance its in-house development programmes.
Led by Mike Romanos, CEO, Crescendo leverage its VH platform to develop human VH antibody fragment therapeutics focused topical biologic for psoriasis and multivalent products for oncology indications.
FinSMEs
03/04/2014